Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 473.

https://doi.org/10.1182/blood-2023-172704

Published: 2023

Journal Articles

IPSS-M for Transplant Decision Making of Patients with Myelodysplastic Syndromes: A Retrospective Single-Center Study

Annalisa Condorelli, Silvia Salmoiraghi, Chiara Pavoni, Matteo Raviglione, Alessia Civini, Alessandro Putelli, Marco Frigeni, Tamara Intermesoli, Federico Lussana, Giulia Quaresmini, Marta Bellini, Maria Chiara Finazzi, Orietta Spinelli, Alessandro Rambaldi

Blood (2023) 142 (Supplement 1): 6449.

https://doi.org/10.1182/blood-2023-187369

Published: 2023

Journal Articles

Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult Patients with Transplant-Associated Thrombotic Microangiopathy: A Real-World Experience

Marta Castelli, Maria Caterina Mico', Anna Grassi, Alessandra Algarotti, Maria Chiara Finazzi, Benedetta Rambaldi, Cristian Meli, Giuliana Rizzuto, Chiara Pavoni, Francesca Vendemini, Marta Verna, Sonia Bonanomi, Adriana Balduzzi, Andrea Biondi, Alessandro Rambaldi, Giacomo Gotti

Blood (2023) 142 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2023-180917

Published: 2023

Journal Articles

Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Blood (2022) 140 (Supplement 1): 10622–10623.

https://doi.org/10.1182/blood-2022-162298

Published: 2022

Journal Articles

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Chiara Paoli, Paola Guglielmelli, Francesco Mannelli, Miriam Borella, Vittorio Rosti, Elisa Rumi, Maria Chiara Finazzi, Oscar Borsani, Carmela Mannarelli, Maria Esposito, Mario Xhani, Lisa Pieri, Tiziano Barbui, Alessandro Rambaldi, Alessandro Vannucchi

Blood (2022) 140 (Supplement 1): 6840–6841.

https://doi.org/10.1182/blood-2022-156566

Published: 2022

Journal Articles

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Blood (2022) 140 (Supplement 1): 1797–1799.

https://doi.org/10.1182/blood-2022-157255

Published: 2022

Journal Articles

The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis

Blood (2021) 138 (Supplement 1): 236.

https://doi.org/10.1182/blood-2021-145116

Published: 2021

Journal Articles

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Alessandra Carobbio, BSc, Elisa Rumi, MD, Valerio De Stefano, MD, Lara Mannelli, MD, Francesco Mannelli, MD, Giada Rotunno, PhD, Giacomo Coltro, MD, Silvia Betti, MD PhD, Chiara Cavalloni, MD, Maria Chiara Finazzi, MD, Juergen Thiele, MD PhD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD

Blood (2019) 134 (Supplement_1): 1657.

https://doi.org/10.1182/blood-2019-124302

Published: 2019

Journal Articles

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Chiara Paoli, PhD, Paola Guglielmelli, MD PhD, Francesco Mannelli, MD, Lara Mannelli, MD, Vittorio Rosti, MD, Maria Chiara Finazzi, MD, Elisa Rumi, MD, Marco Ruggeri, Alessandro Pancrazzi, PhD, Carmela Mannarelli, PhD, Guido Finazzi, MD, Maria Luisa Ferrari, BSc, Laura Lissandrini, BSc, Duccio Fantoni, RN, Giovanni Barosi, Mario Cazzola, MD, Tiziano Barbui, MD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1662.

https://doi.org/10.1182/blood-2019-122837

Published: 2019

Journal Articles

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Blood (2019) 134 (18): 1498–1509.

https://doi.org/10.1182/blood.2019000428

Published: 2019

Includes: Supplemental data

Journal Articles

Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study

Maria Mico', Alessandra Algarotti, MD, Anna Grassi, MD, Chiara Pavoni, Statistician, Francesco Onida, MD, Nicola Mordini, Maria Luisa Ferrari, Federico Lussana, MD PhD, Maria Chiara Finazzi, MD, Daniela Taurino, MD, Chiara Capelli, Martino Introna, MD, Alessandro Rambaldi, MD PhD

Blood (2018) 132 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2018-99-118444

Published: 2018

Journal Articles

Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 321.

https://doi.org/10.1182/blood.V130.Suppl_1.321.321

Published: 2017

Journal Articles

Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms

Tiziano Barbui, MD, Valerio De Stefano, MD, Alessandra Carobbio, MSc, Vincenzo Di Lazzaro, MD, Paola Guglielmelli, MD PhD, Giuseppe Gaetano Loscocco, MD, Alessandra Iurlo, MD PhD, Daniele Cattaneo, MD, Agostino Cortelezzi, Prof, Silvia Betti, MD, Elena Rossi, MD, Maria Chiara Finazzi, MD, Guido Finazzi, MD, Bruno Censori, MD, Mario Cazzola, MD, Elisa Rumi, MD, Marta Bellini, MD, Francisco Cervantes, MD, Eduardo Arellano-Rodrigo, MD, Elena Elli, MD, Maria Luigia Randi, MD, Irene Bertozzi, MD, Martin Griesshammer, MD, Parvis Sadjadian, MD, Francesca Palandri, PhD MD, Nicola Vianelli, Massimiliano Bonifacio, MD, Luigi Scaffidi, Juan Carlos Hernandez-Boluda, MD, Montse Gomez, MD, Emma Cacciola, MD, Rossella Rosari Cacciola, MD, Palova Miroslava, MD, Giuseppe Carli, MD, Eloise Beggiato, MD, Martin H Ellis, MD, Caterina Musolino, MD, Gianluca Gaidano, MD PhD, Davide Rapezzi, MD, Alessia Tieghi, MD, Francesca Lunghi, MD, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 202.

https://doi.org/10.1182/blood.V130.Suppl_1.202.202

Published: 2017

Journal Articles

Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial

Blood (2017) 130 (Supplement 1): 4206.

https://doi.org/10.1182/blood.V130.Suppl_1.4206.4206

Published: 2017

Journal Articles

Blast Phase Myeloproliferative Neoplasm: A Mayo Agimm Study of 419 Consecutive Cases

Ayalew Tefferi, MD, Mythri Mudireddy, MBBS, Kebede H. Begna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD, Meera Yogarajah, MD, Valerio De Stefano, MD, Francesco Passamonti, MD, Vittorio Rosti, Maria Chiara Finazzi, MD, Alessandro Rambaldi, MD Prof, Francesco Mannelli, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 2922.

https://doi.org/10.1182/blood.V130.Suppl_1.2922.2922

Published: 2017

Journal Articles

Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation

Blood (2016) 128 (22): 1160.

https://doi.org/10.1182/blood.V128.22.1160.1160

Published: 2016

Journal Articles

Chronic Graft- Versus -Host Disease after Allogeneic Stem Cell Transplant with in Vivo T-Cell Depletion By Alemtuzumab: Incidence, Outcome and Pattern of Organ Involvement

Maria Chiara Finazzi, MD, Cristina Boschini, MSc, Janice Ward, BSc, Charles Craddock, MDPhD, Alessandro Rambaldi, MD, Ram Malladi, MD PhD

Blood (2014) 124 (21): 3912.

https://doi.org/10.1182/blood.V124.21.3912.3912

Published: 2014

Journal Articles

Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients

Josée Golay, PhD, Anna D’amico, PhD, Gianmaria Borleri, Maria Chiara Finazzi, MD, Giulia Quaresmini, MD, Martino Introna, MD, Alessandro Rambaldi, MD

Blood (2013) 122 (21): 3272.

https://doi.org/10.1182/blood.V122.21.3272.3272

Published: 2013

Journal Articles

Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms

Blood (2013) 122 (21): 4068.

https://doi.org/10.1182/blood.V122.21.4068.4068

Published: 2013

Journal Articles

A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results

Alessandro M. Vannucchi, MD, Paola Guglielmelli, MD, Letizia Lupo, MD, Maria Chiara Finazzi, MD, Lorenzo Tozzi, BiSc, Flavia Biamonte, BiSc, Arianna Masciulli, MD, Maria Chiara Susini, MD, Alessandro Pancrazzi, BiSc, Guido Finazzi, MD, Simona Paratore, MD, Roberto Marchioli, Alberto Bosi, Tiziano Barbui, MD, Alessandro Rambaldi, MD, Giovanni Barosi, MD

Blood (2010) 116 (21): 314.

https://doi.org/10.1182/blood.V116.21.314.314

Published: 2010

NARROW

Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT

IPSS-M for Transplant Decision Making of Patients with Myelodysplastic Syndromes: A Retrospective Single-Center Study

Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult Patients with Transplant-Associated Thrombotic Microangiopathy: A Real-World Experience

Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary Myelofibrosis

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Human Umbilical Cord Derived Mesenchymal Stromal Cells to Treat Steroid-Refractory Acute GvHD III/IV or Overlap Syndrome: Interim Analysis of a Multicenter Phase I/II Study

Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms

Blast Phase Myeloproliferative Neoplasm: A Mayo Agimm Study of 419 Consecutive Cases

Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation

Chronic Graft- Versus -Host Disease after Allogeneic Stem Cell Transplant with in Vivo T-Cell Depletion By Alemtuzumab: Incidence, Outcome and Pattern of Organ Involvement

Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients

Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms

A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only